Clinical Trials | November 26, 2025
Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Jaypirca is making waves in the fight against B-cell malignancies
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
Subscribe To Our Newsletter & Stay Updated
